Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein

Microbes and Infection
Rongliang HuYueqiang Xiao

Abstract

Safe and effective vaccination is important for rabies prevention in animals. Although several genetically engineered rabies vaccines have been developed, few have been licensed for use, principally due to biosafety concerns or due to poor efficacy in animal models. In this paper, we describe the construction and characterization of a replication-competent recombinant canine adenovirus type-2 expressing the rabies virus glycoprotein (SRV9 strain) by a different strategy from that reported previously, i.e., the recombinant genome carrying the glycoprotein cDNA was generated by a series of strictly gene cloning steps, infectious recombinant virus was obtained by transfecting the recombinant genome into a canine kidney cell line, MDCK. This recombinant virus, CAV-E3delta-CGS, was subcutaneously injected into dogs. All vaccinated dogs produced effective neutralizing antibodies after one inoculation and a stronger anamnestic immune response was produced after booster injection. The immunized dogs could survive the challenge of 60,000 mouse LD50 CVS-24, which is lethal to all unimmunized dogs and is comparable to the conventional vaccines. The immunity lasts for months with a protective level of neutralizing antibody. This recombinan...Continue Reading

References

Jan 1, 1992·Archives of Virology·K M CharltonJ Armstrong
Jan 1, 1990·The Journal of Infectious Diseases·L PrevecF L Graham
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H S GinsbergG A Prince
Nov 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·T J WiktorM Mackett
Jul 13, 1996·The Veterinary Record·K Stöhr, F M Meslin
Sep 1, 2001·The New England Journal of Medicine·C E RupprechtC A Hanlon
Feb 24, 2004·The Journal of Gene Medicine·Eric J Kremer
Oct 9, 2004·Journal of Clinical Microbiology·David K MeyerholzMark R Ackermann
May 18, 2005·Virus Research·Charles E RupprechtBernhard Dietzschold

❮ Previous
Next ❯

Citations

Jul 18, 2012·Human Gene Therapy Methods·María Mercedes SeguraMiguel Chillón
Sep 23, 2008·Vector Borne and Zoonotic Diseases·Ronglinag HuAnthony R Fooks
Nov 26, 2010·Clinical and Vaccine Immunology : CVI·Zi-Guo YuanXing-Quan Zhu
Dec 23, 2009·PLoS Neglected Tropical Diseases·Dennis SlateCharles E Rupprecht
Oct 20, 2015·Molecular Therapy : the Journal of the American Society of Gene Therapy·Julio Alonso-PadillaAndrew H Baker
May 23, 2015·Applied Microbiology and Biotechnology·R CastroA S Coroadinha
Jul 1, 2008·Advances in Virus Research·Susan A Nadin-Davis, Christine Fehlner-Gardiner
Jan 25, 2008·Veterinary Research·Emiliano Tesoro-CruzAlvaro Aguilar-Setién
Jun 23, 2018·Zoonoses and Public Health·Emelissa J MendozaDavid Safronetz
Jul 15, 2018·Veterinary Research·Florence CliquetFrançois-Xavier Meslin
Sep 28, 2021·Frontiers in Veterinary Science·José M RojasVerónica Martín

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.